

Freedom of Information (Scotland) Act 2002

DATE RECEIVED	08/02/2022	SUBJECT	Prescribing Policy for Benzodiazepines		
PASSED TO	Pharmacy	DATE PASSED	09/02/2022	RESPOND BY	01/03/2022
CATEGORY	Press	FoI NUMBER	2022-058		

Question/s to be Answered

1. Between January 2010 and December 2021, both dates inclusive, please detail any changes, instructions or recommendations of changes discussed at board or IJB level in **prescribing policy** for benzodiazepines. Please note – this could be in relation to reducing or removing prescriptions due to suspected misuse.

Benzodiazepine use is routinely monitored and reviewed at board level and at practice level. Use of these therapeutics also forms part of routine National Therapeutic Indicator performance review.

2. Between January 2010 and December 2021, both date inclusive, please detail any changes, instructions or recommendations of changes discussed at board or IJB level in **prescribing practice** for benzodiazepines. Please note – this could be in relation to reducing or removing prescriptions due to suspected misuse.

Benzodiazepine use is routinely monitored and reviewed at board level and at practice level. Use of these therapeutics also forms part of routine National Therapeutic Indicator performance review. Prescribers routinely review the use of these therapeutics and implement appropriate actions – including dose reductions or stopping this medication.

3. Between January 2010 and December 2021, both date inclusive, please detail any changes, instructions or recommendations of changes discussed at board or IJB level in prescribing policy for gabapentinoids. Please note – this could be in relation to reducing or removing prescriptions due to suspected misuse.

Gabapentinoid use is routinely monitored and reviewed at board level and at practice level. Use of these therapeutics also forms part of routine National Therapeutic Indicator performance review.

4. Between January 2010 and December 2021, both date inclusive, please detail any changes, instructions or recommendations of changes discussed at board or IJB level in prescribing practice for gabapentinoids. Please note – this could be in relation to reducing or removing prescriptions due to suspected misuse.

Gabapentinoid use is routinely monitored and reviewed at board level and at practice level. Use of these therapeutics also forms part of routine National Therapeutic Indicator performance review. Prescribers routinely review the use of these therapeutics and implement appropriate actions – including dose reductions or stopping this medication.

5. Between January 2010 and January 2021, for the month of January in each year, please detail the **number of people prescribed benzodiazepines** for longer than four weeks.

Freedom of Information (Scotland) Act 2002

NHS SHETLAND: Number of Patients with a Prescription for a Benzodiazepine in January plus a benzodiazepine prescription in at least one of the adjacent months (ie December or February) (Excludes any HBP or Dental Prescribing)

Paid Financial Year	Distinct Patient Count
2009	124
2010	135
2011	124
2012	132
2013	129
2014	131
2015	125
2016	132
2017	122
2018	118
2019	118
2020	117

NB:For Paid Financial Year identification:
2009 = FY 2009/2010, reporting months Dec 2009, Jan 2010, Feb 2010.